Anmelden Kostenlos registrieren

OncoSec Medical Inc Vermögensrendite

Was ist das Vermögensrendite von OncoSec Medical Inc?

Vermögensrendite von OncoSec Medical Inc ist -160.62%

Was ist die Definition von Vermögensrendite?



Die Vermögensrendite gibt an, wie rentabel die Vermögenswerte eines Unternehmens bei der Erzielung von Einnahmen sind. Sie wird berechnet, indem das Nettoeinkommen durch die durchschnittliche Bilanzsumme geteilt wird.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Vermögensrendite von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu OncoSec Medical Inc

Was macht OncoSec Medical Inc?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Unternehmen mit vermögensrendite ähnlich OncoSec Medical Inc